---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-001771"
form_type: "8-K/A"
ticker: null
cik: "0001662244"
company_name: "Cyteir Therapeutics, Inc."
filed_at: "2023-02-03T23:59:59+00:00"
generated_at: "2026-06-20T01:09:13.449197+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cyteir cuts 70% of workforce, focuses CYT-0851 on ovarian cancer; cash runway to 2026

## Summary
- Workforce reduced by ~70% to 15 or fewer employees; expects $2.5M-$3M severance charges in Q1 2023.
- CEO Markus Renschler eligible for retention bonus of 150% of target annual bonus if employed through Dec 31, 2023.
- CBO Andrew Gengos separating Feb 3, 2023; CSO Paul Secrist separating Apr 1, 2023; stock options accelerated.
- Phase 2 monotherapy enrollment suspended; focus on CYT-0851 + capecitabine for platinum-resistant ovarian cancer.
- Cash and cash equivalents $147M as of Dec 31, 2022 (unaudited); estimated cash runway into 2026.

## SEC filing metadata
- accession: 0000950170-23-001771
- form_type: 8-K/A
- cik: 0001662244
- company_name: Cyteir Therapeutics, Inc.
- filed_at: 2023-02-03T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 2.05, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662244/000095017023001771/0000950170-23-001771-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662244/000095017023001771/cyt-20230112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-001771
- JSON: https://secwatch.observer/filing/0000950170-23-001771.json
- Plain text: https://secwatch.observer/filing/0000950170-23-001771.txt

## Key facts
- Executive change
  Andrew Gengos departed as Chief Business Officer at Cyteir Therapeutics, Inc..
  - Action: separated
  - Role: Chief Business Officer
  source text: Andrew Gengos, the Company’s Chief Business Officer will separate from the Company effective February 3, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662244/000095017023001771/0000950170-23-001771-index.htm
- Executive change
  Paul Secrist departed as Chief Scientific Officer at Cyteir Therapeutics, Inc..
  - Action: separated
  - Role: Chief Scientific Officer
  source text: Paul Secrist, Ph.D., the Company’s Chief Scientific Officer will separate from the Company effective April 1, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662244/000095017023001771/0000950170-23-001771-index.htm
- Restructurings & Charges
  Cyteir Therapeutics, Inc. announced a restructuring with charges of $2.5 million to $3 million (approximately 70% of the Company’s workforce).
  - Type: restructuring
  - Charge: $2.5 million to $3 million
  - Headcount: approximately 70% of the Company’s workforce
  source text: the Company expects to have 15 or fewer full-time employees. The Company estimates that, in connection with these changes, it will incur aggregate charges of approximately $2.5 million to $3 million, all of which are anticipated to result in future cash expenditures, primarily for one-time employee severance and benefit costs, the majority of which are expected
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662244/000095017023001771/0000950170-23-001771-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.